🏛️ Verified NIH Record • Updated 2026-03-23

A Monotherapy in Subjects With Advanced Solid Tumors (NCT04221204)

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: 3D Medicines (Beijing) Co., Ltd.

🩺 Plain-English Summary (8th-Grade Level)

A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics Profiles, and Preliminary Efficacy of 3D185 Monotherapy in Subjects with Advanced Solid Tumors

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (13 items) and avoid the listed exclusions (32 items).

Location: Sarcoma Oncolog Research Center — Santa Monica, California

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria: Subjects who meet any of the following criteria should be excluded from the study:
  • Subjects who received other investigational products or devices in other clinical trials within 4 weeks before the first dose;
  • Subjects who received anti-tumor therapy (except for mitomycin, nitrosourea, and fluorouracil oral drugs) within 4 weeks before the first dose, including but not limited to chemotherapy, radiotherapy (palliative radiotherapy is completed at least 2 weeks before the first dose can enroll), targeted therapy or immunotherapy. Note: Mitomycin and nitrosourea have been treated within 6 weeks after the last dose; oral fluorouracil such as tegafur and capecitabine has been treated within 2 weeks after the last dose.
  • Subjects who previously received FGFR1-3 specific inhibitor therapy.
  • Subjects who have previous toxicity of anti-tumor therapy that has not been returned to level 0 or 1. (Alopecia, chemotherapy-induced peripheral neurotoxicity and ototoxicity ≤ Grade 2 can enroll);
  • Subjects who received a CYP3A4 and/or CYP2C8 strong inhibitor or a CYP3A4 strong inducer (see Appendix 6) within 7 days prior to the first dose, and need to continue using these drugs;
  • Subjects who have any of the following eye diseases/conditions:
  • History of retinal pigment epithelial detachment (RPED);
  • History of laser treatment or intraocular injection for macular degeneration;
  • History of dry or wet age-related macular degeneration;
  • History of retinal vein occlusion (RVO);
  • History of retinal degenerative diseases;

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

  • Sarcoma Oncolog Research Center — Santa Monica, California
  • Shanghai East Hospital — Shanghai,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗